Audentes Therapeutics Inc

Audentes Therapeutics — Technical Presentation (January 2018)

21 slides from Audentes Therapeutics's technical presentation, Jan 4, 2018

  1. Slide 1: ASPIRO Study Interim data as of December 21, 2017

    ASPIRO Study Interim data as of December 21, 2017 Exhibit 99.2

  2. Slide 2: Safe Harbor

    Safe Harbor Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause event

  3. Slide 3: AT132 Overview

    AUDENTES > AT132 OVERVIEW Courageous Patients. Bold Effort.

  4. Slide 4: XLMTM Overview: A fatal disease with no treatment options

    Serious, life-threatening rare disease Significant impairment of respiratory and neuromuscular function Estimated 50% mortality by 18 months Incidence: 1 in 50K newborn males Monogenic, well-understood biology MTM1 gene encodes myotubularin, an enzyme required for normal development and function of

  5. Slide 5: AT132 Clinical Development Program

    AT132 Clinical Development Program INCEPTUS Prospective Natural History Run-in Study in XLMTM Patients N≈16 Longitudinal baseline and within-patient control for ASPIRO Facilitates enrollment in and operational aspects of ASPIRO ASPIRO A Phase 1/2 Clinical Study in XLMTM Patients N=12 Assessment of s

  6. Slide 6: ASPIRO: To Aspire...

    AUDENTES > ASPIRO: TO ASPIRE... Courageous Patients. Bold Effort.

  7. Slide 7: ASPIRO Phase 1/2 Clinical Study

    ASPIRO Phase 1/2 Clinical Study Baseline AT132 administration Weeks 5–9 taper Long-term follow-up 6 mos. Inclusion Criteria Subject is male <5 yrs old, or enrolled in INCEPTUS Genetically confirmed XLMTM Requires ventilator support Key Efficacy Assessments Neuromuscular CHOP INTEND MFM-20 Bayley III

  8. Slide 8: ASPIRO Clinical Study Sites

    ASPIRO Clinical Study Sites Same study sites as INCEPTUS natural history run-in study

  9. Slide 9: ASPIRO Cohort

    ASPIRO Cohort 1 All four Cohort 1 patients rolled over from INCEPTUS to ASPIRO CONFIDENTIAL ASPIRO Follow-up Interim data as of December 21, 2017 Age at baseline and follow up duration Age at ASPIRO Baseline (yrs) 0.8 2.6 4.1 4.0 Subject Number Pt 1 Pt 3 Pt 2 Pt 4 (Ctl) 0 -12 months 1 year 2 years 4

  10. Slide 10: Safety and Tolerability

    AUDENTES > SAFETY AND TOLERABILITY Courageous Patients. Bold Effort.

  11. Slide 11: AT132 Safety and Tolerability Profile at 1 x 10^14 vg/kg

    No tolerability issues during study drug administration Two serious adverse events (SAEs), both in Patient 3 Hospitalization for pneumonia (week 2), not treatment-related Hospitalization for GI infection and elevated troponin levels (week 7), is responding to IV steroids and supportive care; probabl

  12. Slide 12: Neuromuscular Function

    AUDENTES > NEUROMUSCULAR FUNCTION Courageous Patients. Bold Effort.

  13. Slide 13: Significant Improvements in Neuromuscular Function (CHOP-INTEND)

    Significant Improvements in Neuromuscular Function as Assessed by the CHOP-INTEND Scale CONFIDENTIAL Maximum score = 64 points (normally reached by 3-6 months of age) Interim data as of December 21, 2017 CHOP-INTEND score Pt # Median score in INCEPTUS Baseline Score in ASPIRO Most recent score (Wk)

  14. Slide 14: Multiple Motor Milestones Achieved at 12 Weeks in First Treated Patient

    CONFIDENTIAL Multiple Motor Milestones Achieved at 12 Weeks in First Treated Patient Interim data as of December 21, 2017 First-year developmental milestones in healthy children Patient 1 Baseline Week 12 Rolling over Head Control Sitting unassisted >5 sec - - - + + +

  15. Slide 15: Respiratory Function

    AUDENTES > RESPIRATORY FUNCTION Courageous Patients. Bold Effort.

  16. Slide 16: Significant Improvements in Respiratory Function (MIP)

    Significant Improvements in Respiratory Function as Assessed by Maximal Inspiratory Pressure (MIP) Estimated normal minimal pressures in healthy children Interim data as of December 21, 2017 Maximum Inspiratory Pressure (cmH2O) Pt # Median Pressure in INCEPTUS Baseline Pressure in ASPIRO Most recent

  17. Slide 17: Qualitative Assessments

    AUDENTES > QUALITATIVE ASSESSMENTS Courageous Patients. Bold Effort.

  18. Slide 18: Progressive Qualitative Improvements Observed in Disease Severity

    CONFIDENTIAL Increased trunk and limb strength and activity Early indicator of gross muscle function improvement Velocity and accuracy of movement has also improved Reductions in ventilator settings (pressure, rate and volume of mechanical ventilation) Patients 1 and 2 First step toward weaning off

  19. Slide 19: Patient CHOP-INTEND video assessments baseline vs Week

    Patient 1 chop intend video assessments baseline vs Week 12

  20. Slide 20: ASPIRO Key Findings and Program Next Steps

    Six adverse events to date (3 treatment-related); all resolved or responding to treatment Significant improvements in neuromuscular function as assessed by the CHOP-INTEND scale Multiple developmental milestones achieved at 12 weeks in Patient 1 Significant improvements in respiratory function as as

  21. Slide 21: ASPIRO Study Interim data as of December 21, 2017

    ASPIRO Study Interim data as of December 21, 2017

Audentes Therapeutics — Technical Presentation (January 2018) on 6ix